Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Fuji
Mallinckrodt
Chubb
Deloitte
McKinsey
Cerilliant
Baxter
Healthtrust

Generated: December 12, 2017

DrugPatentWatch Database Preview

Bayer Company Profile

« Back to Dashboard

What is the competitive landscape for BAYER, and when can generic versions of BAYER drugs launch?

BAYER has one hundred and twenty-seven approved drugs.

There are sixty-two US patents protecting BAYER drugs and there have been three Paragraph IV challenges on BAYER drugs in the past three years.

There are one thousand six hundred and seventy-five patent family members on BAYER drugs in seventy-six countries and one hundred and eighty-three supplementary protection certificates in sixteen countries.

Summary for Bayer

International Patents:1675
US Patents:62
Tradenames:110
Ingredients:75
NDAs:127
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Bayer HlthcareCIPRO XRciprofloxacin; ciprofloxacin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021473-002Aug 28, 2003DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Bayer Healthcare LlcGYNE-LOTRIMIN 3clotrimazoleTABLET;VAGINAL020525-001Jul 29, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareULTRAVIST 370iopromideINJECTABLE;INJECTION020220-001May 10, 1995RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bayer PharmsRADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)albumin iodinated i-125 serumINJECTABLE;INJECTION017846-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareYAZdrospirenone; ethinyl estradiolTABLET;ORAL021676-001Mar 16, 2006ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareQUINACTquinidine gluconateTABLET;ORAL086099-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareADEMPASriociguatTABLET;ORAL204819-001Oct 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bayer PharmsMEZLINmezlocillin sodium monohydrateINJECTABLE;INJECTION062372-002May 13, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareCIPRO XRciprofloxacin; ciprofloxacin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021473-001Dec 13, 2002DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
BayerMEASURINaspirinTABLET, EXTENDED RELEASE;ORAL016030-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bayer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare LlcMYCELEXclotrimazoleCREAM;TOPICAL018183-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Bayer HlthcareNATAZIAdienogest; estradiol valerateTABLET;ORAL022252-001May 6, 2010► Subscribe► Subscribe
Bayer HlthcareCIPROciprofloxacinFOR SUSPENSION;ORAL020780-002Sep 26, 1997► Subscribe► Subscribe
Bayer HlthcareMAGNEVISTgadopentetate dimeglumineINJECTABLE;INJECTION019596-001Jun 2, 1988► Subscribe► Subscribe
Bayer HlthcareCIPROciprofloxacin hydrochlorideTABLET;ORAL019537-003Oct 22, 1987► Subscribe► Subscribe
Bayer PharmsADALATnifedipineCAPSULE;ORAL019478-002Sep 17, 1986► Subscribe► Subscribe
Bayer Healthcare LlcZEGERID OTComeprazole; sodium bicarbonateFOR SUSPENSION;ORAL022283-001Jun 17, 2013► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-004Mar 14, 2011► Subscribe► Subscribe
Bayer PharmsBAYCOLcerivastatin sodiumTABLET;ORAL020740-001Jun 26, 1997► Subscribe► Subscribe
Bayer HlthcareAVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINERmoxifloxacin hydrochlorideSOLUTION;IV (INFUSION)021277-001Nov 30, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAYER drugs

Drugname Dosage Strength Tradename Submissiondate
azelaic acidTopical Foam15%FINACEA9/14/2017
regorafenibTablets40 mgSTIVARGA9/27/2016
drospirenone and estradiolTablets0.25 mg/0.5 mgANGELIQ1/8/2015
sorafenib tosylateTablets200 mgNEXAVAR2/28/2014
moxifloxacin hydrochlorideInjection1.6 mg/mLAVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER2/7/2014
drospirenone and ethinyl estradiol and levomefolate calcium and levomefolate calciumTablets3 mg/0.02 mg/0.451 mg and 0.451 mgBEYAZ11/13/2012
drospirenone and ethinyl estradiol and levomefolate calcium and levomefolate calciumTablets3 mg/0.03 mg/0.451 mg and 0.451 mgSAFYRAL9/28/2012
azelaic acidGel15%FINACEA7/27/2012
vardenafil hydrochlorideOrally Disintegrating Tablets10 mgSTAXYN12/22/2011
drospirenone and ethinyl estradiol and levomefolateTablets3 mg/0.02 mg/0.451 mg and 0.451 mgBEYAZ11/21/2011
desonideGel0.05%DESONATE12/1/2010
estradiol valerate and dienogestTablets3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mgNATAZIA10/22/2010
omeprazole and sodium bicarbonateCapsules20 mg/1100 mgZEGERID OTC4/20/2010
ciprofloxacinOral Suspension250 mg/5 mL and 500 mg/ 5 mLCIPRO10/16/2009
vardenafil hydrochlorideTablets2.5 mgLEVITRA9/4/2009
vardenafilTablets5 mg ad 10 mgLEVITRA7/10/2009
vardenafil hydrochlorideTablets20 mgLEVITRA3/5/2009
drospirenone and estradiolTablets0.5 mg/1 mgANGELIQ12/26/2007
drospirenone and ethinyl estradiolTablets3 mg/0.02 mgYAZ9/29/2006
estradiolTransdermal System0.05 mg/day and 0.1 mg/dayCLIMARA9/12/2005
acarboseTablets25 mg, 50 mg and 100 mgPRECOSE3/22/2005
drospirenone and ethinyl estradiolTablets3 mg/0.03 mgYASMIN1/7/2005

Premature patent expirations for BAYER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe
► Subscribe ► Subscribe
► Subscribe ► Subscribe

Non-Orange Book Patents for Bayer

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,298,515Vitamin formulation► Subscribe
7,029,659Mousse composition► Subscribe
6,939,550 Stabilized antihistamine syrup► Subscribe
8,795,635Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses► Subscribe
7,645,803Saccharide foamable compositions► Subscribe
7,704,518Foamable vehicle and pharmaceutical compositions thereof► Subscribe
2,010,040,561► Subscribe
8,486,374Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses► Subscribe
7,704,9992-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
RE45198Omeprazole solution and method for using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bayer Drugs

Country Document Number Estimated Expiration
European Patent Office1888067► Subscribe
New Zealand520121► Subscribe
New Zealand526847► Subscribe
World Intellectual Property Organization (WIPO)0249675► Subscribe
Argentina025001► Subscribe
Germany59706887► Subscribe
New Zealand538275► Subscribe
Cyprus1118394► Subscribe
Slovenia918791► Subscribe
Denmark1506193► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bayer Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0020France► SubscribePRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
C/GB01/012United Kingdom► SubscribePRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
C/GB11/054United Kingdom► SubscribePRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
14/028Ireland► SubscribePRODUCT NAME: RIOCIGUAT OR A SALT, ISOMER OR HYDRATE THEREOF; REGISTRATION NO/DATE: EU/1/13/907/001-015 20140327
2107069/01Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
41/2009Austria► SubscribePRODUCT NAME: PACLITAXEL ALBUMIN
/2005Austria► SubscribePRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005
2011005,C0984957Lithuania► SubscribePRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
90050-1Sweden► SubscribePRODUCT NAME: REGORAFENIB
C0022France► SubscribePRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Daiichi Sankyo
Moodys
Federal Trade Commission
Boehringer Ingelheim
US Department of Justice
Healthtrust
Novartis
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot